Clinical Trial

Functionality of Albumin in the Context of Hemodialysis

Study acronym: FACED
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin. The aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties. Our own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. It also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins. Previous results have mostly been collected in observational studies. As a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.
Trial Details
NCT Number NCT06561191
Lead Sponsor Universität Duisburg-Essen
Conditions Albumin, Dialysis, Redox State, Uremic; Toxemia
Enrollment 50 participants
Start Date 2024-08-01
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-19